GB9125623D0 - Cell modification - Google Patents

Cell modification

Info

Publication number
GB9125623D0
GB9125623D0 GB9125623A GB9125623A GB9125623D0 GB 9125623 D0 GB9125623 D0 GB 9125623D0 GB 9125623 A GB9125623 A GB 9125623A GB 9125623 A GB9125623 A GB 9125623A GB 9125623 D0 GB9125623 D0 GB 9125623D0
Authority
GB
Grant status
Grant
Patent type
Prior art keywords
cell modification
modification
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9125623A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynal AS
Original Assignee
Dynal AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

GB9125623A 1991-12-02 1991-12-02 Cell modification Pending GB9125623D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9125623A GB9125623D0 (en) 1991-12-02 1991-12-02 Cell modification

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9125623A GB9125623D0 (en) 1991-12-02 1991-12-02 Cell modification
AU3084492A AU3084492A (en) 1991-12-02 1992-12-02 Modified mammalian stem cell blocking viral replication
PCT/EP1992/002787 WO1993011230A1 (en) 1991-12-02 1992-12-02 Modified mammalian stem cell blocking viral replication

Publications (1)

Publication Number Publication Date
GB9125623D0 true GB9125623D0 (en) 1992-01-29

Family

ID=10705573

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9125623A Pending GB9125623D0 (en) 1991-12-02 1991-12-02 Cell modification

Country Status (2)

Country Link
GB (1) GB9125623D0 (en)
WO (1) WO1993011230A1 (en)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709309B1 (en) * 1993-08-25 1995-11-10 Centre Nat Rech Scient cellular compositions, preparation and therapeutic uses.
WO1996033281A1 (en) * 1995-04-20 1996-10-24 Chiron Corporation High efficiency ex vivo transduction of hematopoietic stem cells by recombinant retroviral preparations
WO1997007808A1 (en) * 1995-08-25 1997-03-06 The Regents Of The University Of California Chimeric antiviral agents which incorporate rev binding nucleic acids
US6426412B1 (en) * 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
US6316210B1 (en) 1995-12-20 2001-11-13 Subsidiary No. 3, Inc. Genetic suppressor elements against human immunodeficiency virus
FR2746109B1 (en) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Medium for conservation biological material
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6537972B1 (en) 1997-06-02 2003-03-25 Subsidiary No. 3., Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6001558A (en) * 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
DE69838584D1 (en) 1997-08-04 2007-11-29 Cell Genesys Inc Enhancer of human glandular kallikrein gene vectors containing it and methods for its use
EP2386630A1 (en) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
WO1999053031A3 (en) * 1998-04-08 1999-12-16 Max Planck Gesellschaft Process for producing cell clone libraries
WO1999057265A1 (en) * 1998-05-04 1999-11-11 Julianna Lisziewicz Chimeric decoy rnas having synergistic anti-hiv activity
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039302A3 (en) 1998-12-31 2001-01-04 Chiron Corp Improved expression of hiv polypeptides and production of virus-like particles
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
JP2003518363A (en) 1999-04-30 2003-06-10 カイロン エセ.ピー.アー. Saved Neisseria antigen
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1801219B1 (en) 1999-10-29 2015-10-14 GlaxoSmithKline Biologicals S.A. Neisserial antigenic peptides
JP2003516731A (en) 1999-11-18 2003-05-20 カイロン コーポレイション Human fgf-21 gene and gene expression products
JP2003520248A (en) 2000-01-17 2003-07-02 カイロン エセ.ピー.アー. N. Outer membrane vesicles containing meningitidis serotype b outer membrane protein (OMV) vaccines
WO2001057245A3 (en) * 2000-02-04 2002-06-27 Leuven K U Res & Dev Hiv-1 resistance assay
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
EP2075255A1 (en) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Human FGF-23 gene and gene expression products
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
JP5363695B2 (en) 2000-06-15 2013-12-11 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Polynucleotides related to colon cancer
US6613506B1 (en) 2000-11-28 2003-09-02 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081642A3 (en) 2001-04-06 2003-11-20 Imran Ahmad Gene brcc-3 and diagnostic and therapeutic uses thereof
JP4353701B2 (en) 2001-05-08 2009-10-28 セルテック アール アンド ディー インコーポレイテッド Methods of modulating immune function in primates using Foxp3 protein
EP1409694A4 (en) 2001-07-05 2006-02-08 Chiron Corp Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
JP5033303B2 (en) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Polynucleotides encoding antigenic type c hiv polypeptide, polypeptides and uses thereof
US7498407B2 (en) 2001-11-09 2009-03-03 Georgetown University Vascular endothelial cell growth inhibitor, VEGI-192a
CN100515494C (en) 2001-12-12 2009-07-22 启龙有限公司 Immunisation against chlamydia trachomatis
EP2075346A3 (en) 2002-01-08 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Gene products differentially expressed in cancerous breast cells and their methods of use
US7615229B2 (en) 2002-03-15 2009-11-10 Wyeth Holdings Corporation Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity
EP1501855A4 (en) 2002-03-21 2006-02-22 Sagres Discovery Inc Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
CN1878794B (en) 2002-10-08 2011-11-30 里纳特神经系统学公司 Ngf opioid antagonist and an agent of use in the treatment of pain
KR101250818B1 (en) 2002-12-24 2013-04-15 리나트 뉴로사이언스 코프. Anti-ngf antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
JP2006525960A (en) 2003-02-19 2006-11-16 ライナット ニューロサイエンス コーポレイション Methods for treating pain by administration of nerve growth factor agonists and NSAID, and compositions containing them
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP1619951B1 (en) 2003-04-21 2011-06-22 Epeius Biotechnologies Corporation Methods and compositions for treating disorders
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US9532994B2 (en) 2003-08-29 2017-01-03 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
WO2005062955A3 (en) 2003-12-23 2006-06-22 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
ES2407465T3 (en) 2004-03-29 2013-06-12 Galpharma Co., Ltd. New modified galectin 9 protein and use thereof
CA2562024C (en) 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
ES2673972T3 (en) 2004-07-09 2018-06-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of the glycoprotein G of the Hendra and Nipah virus
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
KR101068289B1 (en) 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 Antibodies directed against amyloid-beta peptide and methods using same
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
RU2486204C2 (en) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Cd26 antibodies and methods of using them
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
JP2009528291A (en) 2006-02-27 2009-08-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Oxysterols compound and the hedgehog pathway
KR101510753B1 (en) 2006-06-07 2015-04-10 바이오얼라이언스 씨.브이. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
WO2009030978A3 (en) 2006-06-09 2009-06-11 Novartis Ag Conformers of bacterial adhesins
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
WO2008116116A3 (en) 2007-03-20 2008-12-18 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
WO2008124176A3 (en) 2007-04-10 2009-03-19 Univ Tulane Soluble and membrane-anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP2011505357A (en) 2007-12-03 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Hedgehog signaling, osteoinductive, anti adipogenesis, and oxysterols for active wnt signaling
WO2009126306A3 (en) 2008-04-10 2010-04-22 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
WO2010039536A3 (en) 2008-09-23 2010-11-04 President And Fellows Of Harvard College Sirt4 and uses thereof
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010086828A3 (en) 2009-02-02 2010-10-07 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
EP2403526A2 (en) 2009-03-06 2012-01-11 Novartis AG Chlamydia antigens
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
JP5830009B2 (en) 2009-04-14 2015-12-09 ノバルティス アーゲー Composition for immunizing against Staphylococcusaureus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011091272A1 (en) 2010-01-21 2011-07-28 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
EP2598126A2 (en) 2010-07-30 2013-06-05 Saint Louis University Methods of treating pain
WO2012064743A3 (en) 2010-11-08 2012-07-19 The Johns Hopkins University Methods for improving heart function
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012075243A3 (en) 2010-12-01 2012-12-27 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
WO2013039996A4 (en) 2011-09-13 2013-05-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
CN104284674A (en) 2012-05-04 2015-01-14 辉瑞公司 Prostate-associated antigens and vaccine-based immunotherapy regimens
US9999683B2 (en) 2013-03-14 2018-06-19 Epeius Biotechnologies Corporation Method for identifying and treating a patient having tumor lesions comprising administering a gene therapy retroviral vector particle comprising a mutated HSV-thymidine kinase (HSV-TK) polynucleotide
EP2991652A4 (en) 2013-05-02 2016-12-07 Univ California Bone-selective osteogenic oxysterol-bone targeting agents
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
KR20170073593A (en) 2014-09-09 2017-06-28 유넘 테라퓨틱스 Chimeric receptors and uses thereof in immune therapy
JP2018527922A (en) 2015-08-19 2018-09-27 ファイザー・インク Tissue factor pathway inhibitor antibodies and uses thereof
WO2017066561A3 (en) 2015-10-16 2017-06-08 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
KR20180064541A (en) 2015-10-23 2018-06-14 화이자 인코포레이티드 Wherein -il-2 antibodies, and compositions and the use thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
WO1989012461A1 (en) * 1988-06-16 1989-12-28 St. Louis University Antagonists of viral transactivating proteins
GB8929297D0 (en) * 1989-12-29 1990-02-28 Dynal As Method of separation
EP0511285A4 (en) * 1990-01-18 1993-05-26 Us Commerce Vector with multiple target response elements affecting gene expression
DE4126484A1 (en) * 1991-08-10 1993-02-11 Bayer Ag Anti-sense-RNA expression vectors - contain hybrid promoter sequences and viral DNA sequences i.e. HIV, in anti-sense direction, useful in prodn. of HIV-resistant cells

Also Published As

Publication number Publication date Type
WO1993011230A1 (en) 1993-06-10 application

Similar Documents

Publication Publication Date Title
US5143923B1 (en) Benzoisothiazole-and benzisoxazole-3-carboxamides
KR0109904Y1 (en) Automizer
DE4092685D2 (en) Mehrkomponenten-kleb- und -werkstoffverarbeitungssystem
EP0442596A3 (en) Echelle-polychromator
RU1785651C (en) Gonioscope
GB2252341B (en) Stormfence
RU1806808C (en) Puzzle-game
EP0531814A3 (en) Tool-gripper
DE59109027D1 (en) Arylpyridazinone
DE69116171D1 (en) Photo- und biologisch-abbaubare polyethen-copolymere
DE69125374D1 (en) Endonukleasen
DE59108981D1 (en) Schlägerbespannungskontrollgerät
DE69130869D1 (en) Xanthinderivate
DE69127457D1 (en) 6-0-methylerythromycin a-derivat
DE69129497D1 (en) Restecholöschung
DE69122864D1 (en) Beta-zell-antigen
DE69125712D1 (en) Hüftprothese
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DE69126781D1 (en) Fabry-perot-modulator